Patents Examined by Jasemine C. Chambers
  • Patent number: 5853765
    Abstract: The present invention is directed to the treatment of vascular disorders particularly arteriosclerosis and atherosclerosis in warm-blooded animals. The invention encompasses the ingestion, by warm-blooded animals, of eggs or egg fractions derived from female avians that have been hyperimmunized with specific bacterial antigens or groups of bacterial antigens. The invention is directed to methods of controlling cholesterol levels, lipid deposits, and the development of atheromatous lesions in warm-blooded animals by the ingestion of eggs or fractions thereof produced in female avians hyperimmunized with specific bacterial antigens. The invention is also directed to methods of producing the eggs and to vaccines for hyperimmunization of the female avians.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 29, 1998
    Assignee: DCV, Inc.
    Inventors: Ralph J. Stolle, Lee R. Beck
  • Patent number: 5851521
    Abstract: The present invention relates to replication defective recombinant viruses which contain at least one inserted gene encoding all or part of the protein GAX or of a variant of this protein, and to their therapeutic use, in particular for treating post-angioplastic restenosis.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: December 22, 1998
    Assignee: Case Western Reserve University
    Inventors: Didier Branellec, Kenneth Walsh, Jeffrey M. Isner, Patrice Denefle
  • Patent number: 5851804
    Abstract: Chimeric kanamycin resistance genes are disclosed. The chimeric genes comprise a nucleotide sequence that encodes ANT(4')-IA enzyme operably linked to a heterologous promoter and a heterologous termination sequence. Plasmids that comprise the chimeric kanamycin resistance gene are disclosed. Bacterial cells that comprise the chimeric gene on a plasmid or integrated into the bacterial genome are disclosed. Methods of producing plasmids are disclosed. Pharmaceutical compositions comprising plasmids that include the chimeric genes are disclosed. Methods of enhancing growth of a bacterial cells are disclosed. Plasmid which comprise the chimeric kanamycin resistance gene and the sequences from herpes simplex virus gene HSVgD.sub.2 or human immunodeficiency virus are disclosed.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: December 22, 1998
    Assignee: Apollon, Inc.
    Inventors: Linda Anne Snyder, C. Satishchandran
  • Patent number: 5851762
    Abstract: The present invention is an improved genomic mapping method which is able to generate highly informative polymorphic sites throughout the genome. In addition to being highly polymorphic, the sites can be used to generate patterns that identify allelic and sub-allelic haplotypes associated with the region.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: December 22, 1998
    Assignee: Gene Type AG
    Inventor: Malcolm J. Simons
  • Patent number: 5849996
    Abstract: The present invention relates to non-human transgenic animals which contain a transgene comprising a BCR/ABL gene fusion and which develop leukemia. In a preferred embodiment of the present invention, the transgenic animals exhibit a rapid induction of acute leukemia. The present invention offers the advantage of providing, for the first time, a non-human transgenic animal model system which carries the BCR/ABL gene fusion characteristic of the Philadelphia chromosome and which develops leukemia in a manner directly analogous to the clinical progression of chronic myelogenous leukemia (CML) and/or acute lymphoblastic leukemia (ALL) in humans. This model system for human leukemia may be valuable in obtaining a better understanding of CML and ALL and in developing effective therapeutic regimens.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 15, 1998
    Assignee: Childrens Hospital of Los Angeles
    Inventors: John Groffen, Nora Heisterkamp, Paul K. Pattengale
  • Patent number: 5849994
    Abstract: HIV-1 does not cause disease in any non-human species. Thus, there is no animal model system to evaluate the efficacy of strategies aimed at preventing or ameliorating disease caused by this virus. The instant invention provides an animal model for HIV-1 induced disease, virus for generating such model animals, and methods for generating pathogenic SHIV.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: December 15, 1998
    Assignee: University of Kansas Medical Center
    Inventor: Opendra Narayan
  • Patent number: 5849993
    Abstract: Transgenic mice carrying a recombinant DNA construct comprising the gene encoding diphtheria toxin A chain operably linked to a osteocalcin promoter. The transgenic mice can be used as a model for metabolic bone diseases since they have decreased bone mass associated with a marked reduction in the number of osteoblasts.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: December 15, 1998
    Assignee: Hoechst Japan Limited
    Inventors: Norihiro Tada, Masahiro Sato, Takashi Kobayashi, Toru Ikeda, Katsuiku Hirokawa
  • Patent number: 5847257
    Abstract: The present invention relates to a transgenic mouse deficient in T-cells, which is provided by fusing human heat shock protein (Hsp) gene with H2K promoter and transferring it to a mouse. Transgenic mouse line with a shrunken thymus and edficient in T-cells not having mature T-cells can be obtained.
    Type: Grant
    Filed: November 16, 1995
    Date of Patent: December 8, 1998
    Assignee: Jeongsun SEO
    Inventors: Jeong-Sun Seo, Soonhee Kim, Woong-Yang Park
  • Patent number: 5846719
    Abstract: The invention provides a method of tracking, identifying, and/or sorting classes or subpopulations of molecules by the use of oligonucleotide tags. Oligonucleotide tags of the invention comprise oligonucleotides selected from a minimally cross-hybridizing set. Preferably, such oligonucleotides each consist of a plurality of subunits 3 to 9 nucleotides in length. A subunit of a minimally cross-hybridizing set forms a duplex or triplex having two or more mismatches with the complement of any other subunit of the same set. The number of oligonucleotide tags available in a particular embodiment depends on the number of subunits per tag and on the length of the subunit. An important aspect of the invention is the use of the oligonucleotide tags for sorting polynucleotides by specifically hybridizing tags attached to the polynucleotides to their complements on solid phase supports.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: December 8, 1998
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Sydney Brenner, Glenn Albrecht, Stephen C. Macevicz
  • Patent number: 5843712
    Abstract: This invention provides a method of expressing a multimeric polypeptide. This invention also provides a method of expressing biologically active recombinant antibodies. This invention also provides an expression cell line capable of producing multimeric polypeptides or biologically active recombinant antibodies. This invention also provides methods of producing biologically active recombinant antibodies or multimeric polypeptides. This invention also provides a transgenic animal comprising the expression cell line capable of producing biologically active recombinant antibodies or multimeric polypeptides. Also, this invention provides a method for preventing infectious diseases associated with arthropods.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: December 1, 1998
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Beth Cindy Levine
  • Patent number: 5843738
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: December 1, 1998
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Christopher K. Mirabelli
  • Patent number: 5843425
    Abstract: A method of preparing swine donor tissue which includes hematopoietic stem cells and T cells for transplantation into a recipient mammal other than a swine. The method includes the swine donor tissue with an antibody which binds the epitope recognized by the mAb 2-6-15 monoclonal antibody. The binding facilitates depletion of T cells about as efficiently or more efficiently than does the mAb 2-6-15 monoclonal antibody and results in about the same or less depletion of stem cells as does the mAb 2-6-15 monoclonal antibody.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 1, 1998
    Assignee: The General Hospital Corporation
    Inventors: David H. Sachs, J. Scott Arn, Thomas Lorf
  • Patent number: 5840570
    Abstract: This invention relates to novel mutant filamentous fungi which are deficient in the gene for the corresponding aspartic proteinase. These organisms are useful production hosts in the production of heterologous polypeptides such as chymosin.
    Type: Grant
    Filed: November 23, 1994
    Date of Patent: November 24, 1998
    Inventors: Randy M. Berka, Kirk J. Hayenga, Virgil B. Lawlis, Michael Ward
  • Patent number: 5837492
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: April 29, 1996
    Date of Patent: November 17, 1998
    Assignees: Myriad Genetics, Inc., Endo Recherche, Inc., HSC Research & Development Limited Partnership, Trustees of the University of Pennsylvaina
    Inventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber
  • Patent number: 5837672
    Abstract: Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: November 17, 1998
    Assignees: Athena Neurosciences, Inc., Eli Lilly and Company, Brigham and Women's Hospital
    Inventors: Dale B. Schenk, Michael G. Schlossmacher, Dennis J. Selkoe, Peter A. Seubert, Carmen Vigo-Pelfrey
  • Patent number: 5837538
    Abstract: Invertebrate and vertebrate patched genes are provided, including the mouse and human patched genes, as well as methods for isolation of related genes, where the genes may be of different species or in the same family. Having the ability to regulate the expression of the patched gene, allows for the elucidation of embryonic development, cellular regulation associated with signal transduction by the patched gene, the identification of agonist and antagonist to signal transduction, identification of ligands for binding to patched, isolation of the ligands, and assaying for levels of transcription and expression of the patched gene.
    Type: Grant
    Filed: October 6, 1995
    Date of Patent: November 17, 1998
    Assignee: Trustees of Leland Stanford, Jr. University
    Inventors: Matthew P Scott, Lisa V. Goodrich, Ronald L. Johnson
  • Patent number: 5837835
    Abstract: Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form more stable duplexes than phosphodiesters with complementary DNA and particularly RNA strands. Further, the phosphoramidate analogs can also form stable triplexes with double-stranded DNA target, where under similar conditions parent phosphodiester compounds failed to do so.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 17, 1998
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz, Jer-kang Chen
  • Patent number: 5837511
    Abstract: The present invention provides replication-deficient non-group C adenoviral vectors. Also provided is a therapeutic method, particularly relating to gene therapy, vaccination, and the like, involving the use of such vectors incorporating a foreign nucleic acid.
    Type: Grant
    Filed: October 2, 1995
    Date of Patent: November 17, 1998
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Erik S. Falck-Pedersen, Ronald G. Crystal, Andrea Mastrangeli, Karil Abrahamson
  • Patent number: 5837233
    Abstract: A method is provided for treatment of a mammalian patient having a tumor by administering to the patient allogenic donor lymphocytes that have been co-cultured in the presence of the patient-derived lymphocytes under conditions sufficient to alloactivate the donor lymphocytes. It is preferred that the donor lymphocytes be introduced intralesionally. This method is preferred for treatment of glioblastoma in humans.
    Type: Grant
    Filed: March 15, 1996
    Date of Patent: November 17, 1998
    Assignee: University Of California
    Inventor: Gale A. Granger
  • Patent number: 5837520
    Abstract: The invention provides a method for purifying viral vectors containing therapeutic genes for use in gene therapy. The invention comprises a method of purification from a cell lysate of a recombinant viral vector containing a therapeutic gene, which comprises: a) treating said lysate with an enzymatic agent that selectively degrades both unencapsulated DNA and RNA; b) chromatographing the treated lysate from step a) on a first resin; and c) chromatographing the eluant from step b) on a second resin; wherein one resin is an anion exchange resin and the other is an immobilized metal ion chromatography (IMAC) resin.
    Type: Grant
    Filed: March 7, 1995
    Date of Patent: November 17, 1998
    Assignee: Canji, Inc.
    Inventors: Paul W. Shabram, Bernard G. Huyghe, Xiaodong Liu, H. Michael Shepard